Lingshi Tan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Virgo Investment Group LLC ("Virgo") announced portfolio company Clinipace Incorporated ("Clinipace"), a full-service Clinical Research Organization ("CRO") headquartered in Raleigh, North Carolina, has merged with dMed Global ("dMed"), a full-service CRO based in Shanghai, China. The strategic merger will create a global mid-size CRO that will deliver innovative solutions to patients worldwide, and meet the needs of fast-moving biotech, pharma, and medical device companies around the world. Together, Clinipace and dMed will offer advanced technologies, ...

Innoforce and dMed Collaborate to Accelerate the Development of Innovative Therapeutics News provided by Share this article Share this article HANGZHOU, China and SHANGHAI, March 2, 2021 /PRNewswire/ -- Innoforce, a biopharmaceutical innovation enabling platform and PDMO (Partner Development and Manufacturing Organization), and dMed, a clinical CRO with strong presence in China and the US - the world's two largest pharmaceutical and drug development markets, have signed an agreement under which the two parties agreed to establish a partnership to identify, assess, and collaborate on the dev...

Regency Centers Invites You to Join Its Fourth Quarter 2020 Earnings Conference Call Regency Centers Invites You to Join Its Fourth Quarter 2020 Earnings Conference Call JACKSONVILLE, Fla., Dec. 16, 2020 — Regency Centers Corporation (The “Company”) (NASDAQ: REG) will announce its Fourth Quarter 2020 earnings results on Thursday, February 11, 2021, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings con...

dMed, a Shangai, China-based clinical CRO, completed a US$100m Series C financing. The round was led by Fidelity Management & Research Company, LLC, with participation from new investors Sequoia Capital China, Kaiser Foundation Hospitals and E Fund, and existing backers Qiming Venture Partners, Lilly Asia Ventures, and Vivo Capital. Led by Founder, Chairman and CEO, Dr. Lingshi Tan, dMed is a full-service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe. The company leverages an...

dMed Completed a US$100 Million Series C Financing News provided by Share this article Share this article SHANGHAI, Dec. 17, 2020 /PRNewswire/ -- dMed, the clinical CRO with strong presence in China and the US, the world's two largest pharmaceutical markets and drug development sites, announced today its successful completion of a US$100 million Series C financing. Led by Fidelity Management & Research Company, LLC, new investors in dMed include Sequoia Capital China, Kaiser Foundation Hospitals and E Fund. They now join the leaders in dMed's angel, A and B rounds, Qiming Venture Partners, Li...